Identification of a disease-defining gene fusion in epithelioid hemangioendothelioma - PubMed (original) (raw)
. 2011 Aug 31;3(98):98ra82.
doi: 10.1126/scitranslmed.3002409.
Andrea Sboner, Andre M Oliveira, Michele R Erickson-Johnson, Jessica Hespelt, Philip J Hanwright, John Flanagan, Yuling Luo, Kerry Fenwick, Rachael Natrajan, Costas Mitsopoulos, Marketa Zvelebil, Benjamin L Hoch, Sharon W Weiss, Maria Debiec-Rychter, Raf Sciot, Rob B West, Alexander J Lazar, Alan Ashworth, Jorge S Reis-Filho, Christopher J Lord, Mark B Gerstein, Mark A Rubin, Brian P Rubin
Affiliations
- PMID: 21885404
- DOI: 10.1126/scitranslmed.3002409
Identification of a disease-defining gene fusion in epithelioid hemangioendothelioma
Munir R Tanas et al. Sci Transl Med. 2011.
Abstract
Integrating transcriptomic sequencing with conventional cytogenetics, we identified WWTR1 (WW domain-containing transcription regulator 1) (3q25) and CAMTA1 (calmodulin-binding transcription activator 1) (1p36) as the two genes involved in the t(1;3)(p36;q25) chromosomal translocation that is characteristic of epithelioid hemangioendothelioma (EHE), a vascular sarcoma. This WWTR1/CAMTA1 gene fusion is under the transcriptional control of the WWTR1 promoter and encodes a putative chimeric transcription factor that joins the amino terminus of WWTR1, a protein that is highly expressed in endothelial cells, in-frame to the carboxyl terminus of CAMTA1, a protein that is normally expressed only in brain. Thus, CAMTA1 expression is activated inappropriately through a promoter-switch mechanism. The gene fusion is present in virtually all EHEs tested but is absent from all other vascular neoplasms, demonstrating it to be a disease-defining genetic alteration. A sensitive and specific break-apart fluorescence in situ hybridization assay was also developed to detect the translocation and will assist in the evaluation of this diagnostically challenging neoplasm. The chimeric WWTR1/CAMTA1 transcription factor may represent a therapeutic target for EHE and offers the opportunity to shed light on the functions of two poorly characterized proteins.
Comment in
- Understanding the enemy.
Velculescu VE, Diaz LA Jr. Velculescu VE, et al. Sci Transl Med. 2011 Aug 31;3(98):98ps37. doi: 10.1126/scitranslmed.3003001. Sci Transl Med. 2011. PMID: 21885403 Free PMC article.
Similar articles
- A novel WWTR1-CAMTA1 gene fusion is a consistent abnormality in epithelioid hemangioendothelioma of different anatomic sites.
Errani C, Zhang L, Sung YS, Hajdu M, Singer S, Maki RG, Healey JH, Antonescu CR. Errani C, et al. Genes Chromosomes Cancer. 2011 Aug;50(8):644-53. doi: 10.1002/gcc.20886. Epub 2011 May 16. Genes Chromosomes Cancer. 2011. PMID: 21584898 Free PMC article. - WWTR1(TAZ)-CAMTA1 reprograms endothelial cells to drive epithelioid hemangioendothelioma.
Driskill JH, Zheng Y, Wu BK, Wang L, Cai J, Rakheja D, Dellinger M, Pan D. Driskill JH, et al. Genes Dev. 2021 Apr 1;35(7-8):495-511. doi: 10.1101/gad.348221.120. Epub 2021 Mar 25. Genes Dev. 2021. PMID: 33766984 Free PMC article. - Epithelioid hemangioendotheliomas with TFE3 gene translocations are compossible with CAMTA1 gene rearrangements.
Lee SJ, Yang WI, Chung WS, Kim SK. Lee SJ, et al. Oncotarget. 2016 Feb 16;7(7):7480-8. doi: 10.18632/oncotarget.7060. Oncotarget. 2016. PMID: 26840265 Free PMC article. - Pleural epithelioid hemangioendothelioma harboring CAMTA1 rearrangement.
Ha SY, Choi IH, Han J, Choi YL, Cho JH, Lee KJ, Sun JM. Ha SY, et al. Lung Cancer. 2014 Mar;83(3):411-5. doi: 10.1016/j.lungcan.2013.12.015. Epub 2014 Jan 7. Lung Cancer. 2014. PMID: 24461304 Review. - Epithelioid hemangioendothelioma-its history, clinical features, molecular biology and current therapy.
Tsuchihashi K, Baba E. Tsuchihashi K, et al. Jpn J Clin Oncol. 2024 Jul 7;54(7):739-747. doi: 10.1093/jjco/hyae037. Jpn J Clin Oncol. 2024. PMID: 38555494 Review.
Cited by
- Comprehensive evaluation of clinical outcomes in hepatic epithelioid hemangioendothelioma subsets: insights from SEER Database and departmental cohort analysis.
Wang B, Chen X, Li R, Ai B, Ye F, Zhao J, Zhang Y, Huang Z, Li Z, Bi X, Zhao H, Cao D, Cai J, Zhou J, Yan T. Wang B, et al. Front Immunol. 2024 Oct 22;15:1491922. doi: 10.3389/fimmu.2024.1491922. eCollection 2024. Front Immunol. 2024. PMID: 39502705 Free PMC article. - Targeting the Hippo pathway in cancer, fibrosis, wound healing and regenerative medicine.
Dey A, Varelas X, Guan KL. Dey A, et al. Nat Rev Drug Discov. 2020 Jul;19(7):480-494. doi: 10.1038/s41573-020-0070-z. Epub 2020 Jun 17. Nat Rev Drug Discov. 2020. PMID: 32555376 Free PMC article. Review. - mRNA Capture Sequencing and RT-qPCR for the Detection of Pathognomonic, Novel, and Secondary Fusion Transcripts in FFPE Tissue: A Sarcoma Showcase.
Decock A, Creytens D, Lefever S, Van der Meulen J, Anckaert J, De Ganck A, Deleu J, De Wilde B, Fierro C, Kuersten S, Luypaert M, Rottiers I, Schroth GP, Steyaert S, Vanderheyden K, Vanden Eynde E, Verniers K, Verreth J, Van Dorpe J, Vandesompele J. Decock A, et al. Int J Mol Sci. 2022 Sep 20;23(19):11007. doi: 10.3390/ijms231911007. Int J Mol Sci. 2022. PMID: 36232302 Free PMC article. - Molecular Pathogenesis and Diagnostic, Prognostic and Predictive Molecular Markers in Sarcoma.
Mariño-Enríquez A, Bovée JV. Mariño-Enríquez A, et al. Surg Pathol Clin. 2016 Sep;9(3):457-73. doi: 10.1016/j.path.2016.04.009. Surg Pathol Clin. 2016. PMID: 27523972 Free PMC article. Review. - Clinical characteristics of Japanese patients with epithelioid hemangioendothelioma: a multicenter retrospective study.
Shiba S, Imaoka H, Shioji K, Suzuki E, Horiguchi S, Terashima T, Kojima Y, Okuno T, Sukawa Y, Tsuji K, Umemoto K, Asagi A, Todaka A, Ueno M, Ikeda M, Morizane C, Furuse J. Shiba S, et al. BMC Cancer. 2018 Oct 19;18(1):993. doi: 10.1186/s12885-018-4934-0. BMC Cancer. 2018. PMID: 30340559 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources